Empowering People to be Ambassadors of their Own Health Since 1997.


Monthly Pubmed Review

Monthly Pubmed Review of the Most Relevant Research on
Hepatitis C
Literature Review, June 2015


Protein C Deficiency in Chronic Hepatitis C: Correlation With Histological Extent of Liver Fibrosis. Saray A1, Mesihovic R2, Vanis N2, Amila M2. Clin Appl Thromb Hemost. 2015 May 24. pii: 1076029615587356. [Epub ahead of print]

The fatigue impact scale for daily use in patients with hepatitis B virus and hepatitis C virus chronic infections. Miranda-Pettersen K1, Morais-de-Jesus M1, Daltro-Oliveira R2, et al. Ann Hepatol. 2015 May-Jun;14(3):310-6.

Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis. Muir AJ1, Poordad F2, Lalezari J3, et al. JAMA. 2015 May 5;313(17):1736-44. doi: 10.1001/jama.2015.3868.

Fixed-dose combination therapy with daclatasvir, asunaprevir, and beclabuvir for noncirrhotic patients with HCV genotype 1 infection. Poordad F1, Sievert W2, Mollison L3, et al. JAMA. 2015 May 5;313(17):1728-35. doi: 10.1001/jama.2015.3860.

Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients with Advanced Liver Disease. Charlton M1, Everson GT2, Flamm SL3, et al. Gastroenterology. 2015 May 15. pii: S0016-5085(15)00682-4. doi: 10.1053/j.gastro.2015.05.010. [Epub ahead of print]

Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: Analysis of phase III ION trials. Alqahtani SA1, Afdhal N2, Zeuzem S3, et al. Hepatology. 2015 May 11. doi: 10.1002/hep.27890. [Epub ahead of print]

Randomized trial of low-dose peginterferon α-2b plus low and escalating doses of ribavirin in older patients with chronic hepatitis C with high viral load genotype 1. Iwasaki Y1,2, Okamoto RI3, Ishii Y4, Araki Y3, Hashimoto N5, Yamamoto K1,6. J Med Virol. 2015 May 22. doi: 10.1002/jmv.24276. [Epub ahead of print]

An open-label Phase 2 study of faldaprevir, deleobuvir, and ribavirin in Japanese treatment-naïve patients with chronic HCV genotype-1 infection. Yatsuhashi H1, Kodani N2, Ugai H2, Omata M3. Hepatol Res. 2015 May 20. doi: 10.1111/hepr.12535. [Epub ahead of print]

Serum and cellular ribavirin pharmacokinetic and concentration-effect analysis in HCV patients receiving sofosbuvir plus ribavirin. Rower JE1, Meissner EG2, Jimmerson LC1, et al. J Antimicrob Chemother. 2015 May 13. pii: dkv122. [Epub ahead of print]


TNF-α Induced by Hepatitis C Virus via TLR7 and TLR8 in Hepatocytes Supports Interferon Signaling via an Autocrine Mechanism. Lee J1, Tian Y1, Chan ST1, Kim JY1, Cho C1, Ou JH1. PLoS Pathog. 2015 May 29;11(5):e1004937. doi: 10.1371/journal.ppat.1004937. eCollection 2015.

Characterization of the transmembrane transport and absolute bioavailability of the HCV protease inhibitor danoprevir. Brennan BJ1, Poirier A, Moreira S, et al. Clin Pharmacokinet. 2015 May;54(5):537-49. doi: 10.1007/s40262-014-0222-6.

Inosine triphosphate pyrophosphohydrolase activity: more accurate predictor for ribavirin-induced anemia in hepatitis C infected patients than ITPA genotype.

Peltenburg NC, Bakker JA, Vroemen WH, de Knegt RJ, Leers MP, Bierau J, Verbon A. Clin Chem Lab Med. 2015 May 13. pii: /j/cclm.ahead-of-print/cclm-2015-0057/cclm-2015-0057.xml. doi: 10.1515/cclm-2015-0057. [Epub ahead of print]

FUSE Binding Protein1 Facilitates Persistent Hepatitis C Virus Replication in Hepatoma Cells by Regulating Tumor Suppressor p53. Dixit U1, Pandey AK1, Liu Z1, Kumar S1, Neiditch M1, Klein KM2, Pandey VN3. J Virol. 2015 May 20. pii: JVI.00729-15. [Epub ahead of print]

Hepatic expression levels of interferons and interferon-stimulated genes in patients with chronic hepatitis C: A phenotype-genotype correlation study. Noureddin M1, Rotman Y2, Zhang F2, et al. Genes Immun. 2015 May 28. doi: 10.1038/gene.2015.11. [Epub ahead of print]

Interaction between the NS4B amphipathic helix, AH2, and charged lipid headgroups alters membrane morphology and AH2 oligomeric state – Implications for the Hepatitis C virus life cycle. Ashworth Briggs EL1, Gomes RG2, Elhussein M3, et al. Biochim Biophys Acta. 2015 Aug;1850(8):1671-7. doi: 10.1016/j.bbamem.2015.04.015. Epub 2015 May 2.


Genetic Variability of Hepatitis C Virus (HCV) 5′ Untranslated Region in HIV/HCV Coinfected Patients Treated with Pegylated Interferon and Ribavirin. Bukowska-Ośko I1, Pawełczyk A1, Perlejewski K1, et al.  PLoS One. 2015 May 1;10(5):e0125604. doi: 10.1371/journal.pone.0125604. eCollection 2015.

Associations between lipodystrophy or antiretroviral medications and cirrhosis in patients with HIV infection or HIV/HCV coinfection. Ioannou GN1, Bryson CL, Weiss NS, Boyko EJ. Eur J Gastroenterol Hepatol. 2015 May;27(5):577-84. doi: 10.1097/MEG.0000000000000290.

Changes in quality of life, healthcare use, and substance use in HIV/hepatitis C coinfected patients after hepatitis C therapy: a prospective cohort study. Yeung MW, Young J, Moodie E, Rollet-Kurhajec KC, et al. HIV Clin Trials. 2015 May-Jun;16(3):100-10. doi: 10.1179/501100000024. Epub 2015 May 14.

Molecular characterization of hepatitis C virus for determination of subtypes and detection of resistance mutations to protease inhibitors in a group of intravenous drug users co-infected with HIV. Silva T1, Cortes Martins H, Coutinho R, Leitão E, Silva R, Pádua E. J Med Virol. 2015 May 1. doi: 10.1002/jmv.24213. [Epub ahead of print]

Hepatitis B virus reactivation after treatment for hepatitis C in hemodialysis patients with HBV/HCV coinfection. Wahle RC1, Perez RM2, et al. Braz J Infect Dis. 2015 May 18. pii: S1413-8670(15)00089-6. doi: 10.1016/j.bjid.2015.04.003. [Epub ahead of print]

Imaging Features and Prognosis of Hepatocellular Carcinoma in Patients with Cirrhosis Who are Coinfected with Human Immunodeficiency Virus and Hepatitis C Virus. Lewin M1, Gelu-Simeon M, Ostos M, et al. Radiology. 2015 May 6:141500. [Epub ahead of print]

Coronary Heart Disease Risk by Framingham Risk Score in Hepatitis C and HIV/Hepatitis C-Coinfected Persons. Chew KW1, Bhattacharya D, McGinnis KA, et al. AIDS Res Hum Retroviruses. 2015 May 11. [Epub ahead of print]

Does hepatitis B virus coinfection have any impact on treatment outcome in hepatitis C patients on hemodialysis? Wahle RC1, de Mello Perez R2, et al. Ann Hepatol. 2015 May-Jun;14(3):317-24.



Plant extracts from Cameroonian medicinal plants strongly inhibit hepatitis C virus infection in vitro. Galani BR1, Sahuc ME2, Njayou FN3, et al. Front Microbiol. 2015 May 15;6:488. doi: 10.3389/fmicb.2015.00488. eCollection 2015.



Assessing the Long-Term Impact of Treating Hepatitis C Virus (HCV)-Infected People Who Inject Drugs in the UK and the Relationship between Treatment Uptake and Efficacy on Future Infections. Bennett H1, McEwan P2, Sugrue D1, Kalsekar A3, Yuan Y3. PLoS One. 2015 May 4;10(5):e0125846. doi: 10.1371/journal.pone.0125846. eCollection 2015.

Intended and unintended effects of large-scale adverse event disclosure: a controlled before-after analysis of five large-scale notifications. Wagner TH1, Taylor T2, Cowgill E2, et al. BMJ Qual Saf. 2015 May;24(5):295-302. doi: 10.1136/bmjqs-2014-003800.

Interferon-Free Regimens for Chronic Hepatitis C: Barriers Due to Treatment Candidacy and Insurance Coverage. Stepanova M1, Younossi ZM. Dig Dis Sci. 2015 May 19. [Epub ahead of print]

Implementing hospital-based baby boomer hepatitis c virus screening and linkage to care: Strategies, results, and costs. Turner BJ1,2, Taylor BS1,2, Hanson JT1,2, et al. J Hosp Med. 2015 May 29. doi: 10.1002/jhm.2376. [Epub ahead of print]

Direct costs of first-generation protease inhibitors for the treatment of genotype 1 chronic hepatitis C viral infection.  Sethi N1, Tapper EB1, Vong A1, Sethi S1, Rourke M1, Afdhal NH1. J Viral Hepat. 2015 May 25. doi: 10.1111/jvh.12421. [Epub ahead of print]

Relevance of low viral load in haemodialysed patients with chronic hepatitis C virus infection. Sperl J1, Frankova S1, Senkerikova R1, et al. World J Gastroenterol. 2015 May 14;21(18):5496-504. doi: 10.3748/wjg.v21.i18.5496.

Identification and Linkage to Care of HCV-Infected Persons in Five Health Centers – Philadelphia, Pennsylvania, 2012-2014. Coyle C, Viner K, Hughes E, Kwakwa H, Zibbell JE, Vellozzi C, Holtzman D. MMWR Morb Mortal Wkly Rep. 2015 May 8;64(17):459-63.

Increases in hepatitis C virus infection related to injection drug use among persons aged ≤30 years – Kentucky, Tennessee, Virginia, and West Virginia, 2006-2012. Zibbell JE, Iqbal K, Patel RC, Suryaprasad A, Sanders KJ, Moore-Moravian L, Serrecchia J, Blankenship S, Ward JW, Holtzman D. MMWR Morb Mortal Wkly Rep. 2015 May 8;64(17):453-8.

HCV antiviral therapy in injection drug users: difficult to treat or easy to cure? Persico M1, Coppola N2, Rosato V3, et al. Ann Hepatol. 2015 May-Jun;14(3):325-32.



Addition of tumor multiplicity improves the prognostic performance of the hepatoma arterial-embolization prognostic score. Park Y1, Kim SU1,2, Kim BK1,2, et al. Liver Int. 2015 May 25. doi: 10.1111/liv.12878. [Epub

High Serum Transforming Growth Factor-β1 Levels Predict Outcome in Hepatocellular Carcinoma Patients Treated with Sorafenib. Lin TH1, Shao YY2, Chan SY3, Huang CY2, Hsu CH4, Cheng AL2. Clin Cancer Res. 2015 May 14. pii: clincanres.1954.2014. [Epub ahead of print]

Control of oxidative stress in hepatocellular carcinoma: Helpful or harmful? Takaki A1, Yamamoto K1. World J Hepatol. 2015 May 8;7(7):968-79. doi: 10.4254/wjh.v7.i7.968.

Novel metronomic chemotherapy and cancer vaccine combinatorial strategy for hepatocellular carcinoma in a mouse model. Tagliamonte M1, Petrizzo A, Napolitano M, ET AL. Cancer Immunol Immunother. 2015 May 6. [Epub ahead of print]

TGF-β1 polymorphism 509 C>T is associated with an increased risk for hepatocellular carcinoma in HCV-infected patients. Ma J1, Liu YC2, Fang Y3, Cao Y3, Liu ZL4. Genet Mol Res. 2015 May 4;14(2):4461-8. doi: 10.4238/2015.May.4.3.

Prevention of liver cancer through the early detection of risk-related behavior among hepatitis B or C carriers. Fan JY1, Huang TJ, Jane SW, Chen MY. Cancer Nurs. 2015 May-Jun;38(3):169-76. doi: 10.1097/NCC.0000000000000153.


Caring Ambassadors Program, Inc. | P.O. Box 1748 | Oregon City, OR 97045 | 503-632-9032 | 503-632-9038 (Fax)